The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...

The U.S. FDA has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea.

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

Americans are getting slimmer. The rise of GLP-1 medications has transformed the way Americans lose weight, and the data supports that: ...

Direct-to-consumer healthcare startup Ro announced Wednesday that its platform will now offer cheaper single-dose vials of the weight loss drug Zepbound through a new partnership with Eli Lillywhich ...

The drugs also slow down how quickly the stomach empties, regulating the speed in which food is digested and absorbed. They ...

Shelby Knowles/Bloomberg via Getty The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug ...

The FDA has announced that popular weight loss medication ... of the drug from the market by early 2025. Tirzepatide is the active ingredient in Eli Lilly's drugs Mounjaro and Zepbound, branded ...

Zepbound got FDA approval to treat obesity and weight loss in November 2023, joining Eli Lilly's other tirzepatide-based drug, Mounjaro. The two drugs, along with Novo Nordisk's (NVO) Ozempic and ...

which doesn't cover drugs solely for weight loss.Without insurance coverage, Zepbound costs $1,060 per month, but Lilly offers discounts, coupons and a lower-priced version that comes in a vial ...